2021
Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates
Datta D, Leslie SN, Wang M, Morozov YM, Yang S, Mentone S, Zeiss C, Duque A, Rakic P, Horvath TL, van Dyck C, Nairn AC, Arnsten AFT. Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates. Alzheimer's & Dementia 2021, 17: 920-932. PMID: 33829643, PMCID: PMC8195842, DOI: 10.1002/alz.12325.Peer-Reviewed Original ResearchConceptsTau pathologyCalcium leakTau phosphorylationNeuronal firingAlzheimer's diseaseEarly tau phosphorylationPyramidal cell dendritesSporadic Alzheimer's diseasePrimary cortical neuronsPotential therapeutic targetCognitive performanceAge-related reductionMacaque dorsolateral prefrontal cortexDorsolateral prefrontal cortexNon-human primatesCalcium dysregulationCell dendritesCortical neuronsCalcium-binding proteinsAD biomarkersPathology markersTherapeutic targetAnimal modelsAged monkeysPrefrontal cortex
2005
NAP: Research and Development of a Peptide Derived from Activity‐Dependent Neuroprotective Protein (ADNP)
Gozes I, Morimoto B, Tiong J, Fox A, Sutherland K, Dangoor D, Holser‐Cochav M, Vered K, Newton P, Aisen P, Matsuoka Y, van Dyck C, Thal L. NAP: Research and Development of a Peptide Derived from Activity‐Dependent Neuroprotective Protein (ADNP). CNS Neuroscience & Therapeutics 2005, 11: 353-368. PMID: 16614735, PMCID: PMC6741706, DOI: 10.1111/j.1527-3458.2005.tb00053.x.Peer-Reviewed Original ResearchConceptsActivity-dependent neuroprotective proteinIntranasal administrationClinical trialsNeuroprotective proteinPhase Ia clinical trialPhase I clinical trialApolipoprotein E deficiencyFurther clinical developmentAdverse side effectsBeta-amyloid peptideAscending dosesElectrical blockadeCardiopulmonary testSingle doseCholinergic toxicityHead injuryIntravenous formulationCognitive dysfunctionDose toxicityElderly volunteersActive doseE deficiencySide effectsAnimal modelsClinical development